Overview

• Biotechnology firm's Q1 net loss per share narrowed to $0.13 from $0.16 yr/yr

• R&D and G&A expenses rose due to lead Parkinson’s program and FX impacts

• Cash and equivalents fell to $16.5 mln from $20.8 mln at year-end 2025

Outlook

• Company expects FDA clearance of GT-02287 IND submission in Q2 2026

• Phase 2 clinical trial of GT-02287 in Parkinson’s disease expected to begin in Q3 2026

• Results from Phase 1b clinical study of GT-02287 expected in Q4 2026

Result Drivers

• R&D SPENDING - Higher research and development costs driven by lead program GT-02287 for Parkinson’s disease and increased personnel expenses

• FX IMPACT - Unfavorable foreign exchange movements increased both R&D and G&A expenses

• PIPELINE PROGRESS - Ongoing Phase 1b clinical study and biomarker data for GT-02287 supported continued investment and expense growth

Company press release: ID:nGNXds2SS

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS		-$0.13

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• Wall Street's median 12-month price target for Gain Therapeutics Inc is $8.00, about 339.6% above its May 8 closing price of $1.82

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.